Unknown

Dataset Information

0

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.


ABSTRACT: BACKGROUND:Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. Here, by means of proteomics and miRNA profiling, we have further unveiled the role of sitagliptin in oxidative stress, as well as the underlying mechanisms. METHODS:Renal cortex samples from 9-month-old wild-type (Wistar), type II diabetic Goto-Kakizaki (GK) and sitagliptin-treated GK rats (GK+Sita) (10 mg kg-1 per day) were subjected to quantitative miRNA transcriptomic array, immunohistochemistry and Western blot studies. Renal GK and GK+Sita samples were also analyzed by differential in-gel electrophoresis. Bioinformatic tools were used to find out the relationships between altered proteins and related miRNA expression. Studies were also carried out in cultured tubular cells to confirm in vivo data. RESULTS:Diabetic GK rats exhibited proteinuria, renal interstitial inflammatory infiltrates and fibrosis, which improved by 20 weeks of sitagliptin treatment. Proteomic analysis of diabetic GK and Wistar rats showed a differential expression of 39 proteins mostly related to oxidative stress and catabolism. In addition, 15 miRNAs were also significantly altered in GK rats. CONCLUSION:Treatment with sitagliptin was associated with modulation of antioxidant response in the diabetic kidney, involving a downregulation of miR-200a, a novel Keap-1 inhibitor and miR-21, coincidentally with the clinical and the morphological improvement. These data further support the concept that DPP-4 inhibitors could exert a direct reno-protective effect in patients with diabetic nephropathy.

SUBMITTER: Civantos E 

PROVIDER: S-EPMC5473486 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.

Civantos Esther E   Bosch Enrique E   Ramirez Elisa E   Zhenyukh Olha O   Egido Jesús J   Lorenzo Oscar O   Mas Sebastián S  

Diabetes, metabolic syndrome and obesity : targets and therapy 20170607


<h4>Background</h4>Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. Here, by means of proteomics and miRNA profiling, we have further unveiled the role of sitagliptin in oxidative stress, as well as the underlying mechanisms.<h4>Methods</h4>Renal cortex samples  ...[more]

Similar Datasets

| S-EPMC7277034 | biostudies-literature
| S-EPMC8356418 | biostudies-literature
| S-EPMC4483240 | biostudies-literature
| S-EPMC3964498 | biostudies-literature
| S-EPMC5370123 | biostudies-literature
| S-EPMC8761405 | biostudies-literature
| S-EPMC2451047 | biostudies-other
| S-EPMC9495519 | biostudies-literature
| S-EPMC3294315 | biostudies-literature
| S-EPMC7445481 | biostudies-literature